Teewinot Life Sciences to Participate at the 31st Annual Piper Jaffray Healthcare Conference in New York TAMPA, Fla., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Teewinot Life Sciences Corporation (“Teewinot” or the “Company”), a global leader in the biosynthetic production of cGMP cannabinoids and cannabinoid...

Teewinot Life Sciences to Participate at the 2nd Annual Cowen Cannabis Conference in Boston TAMPA, Fla., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Teewinot Life Sciences Corporation (“Teewinot” or the “Company”), a global leader in the biosynthetic production of cGMP cannabinoids and cannabinoid...

Teewinot Announces Availability of Cannabinol for Commercial Cannabinoid Market Proprietary manufacturing process, CannSynthesis®, produces cannabinol oil at >98% purity with no detectable THC First company to manufacture cannabinol using chemical synthesis at commercial...

Teewinot Life Sciences Expands First in Class Intellectual Property Portfolio for the Production of Cannabinoids and Novel Derivatives Receives five new patents across strategic areas including biocatalytic manufacturing processes, generation of new chemical entities (NCEs) and cannabinoid formulations Proprietary CannSynthesis®...

Teewinot Life Sciences Announces Executive Leadership Changes TAMPA, Fla., May 22, 2019 (GLOBE NEWSWIRE) -- Teewinot Life Sciences Corporation, a global leader in the biosynthetic development and production of cannabinoids and their derivatives for health and...